文献速递冠心病血脂与心血管预防

抗心绞痛药物:信念与证据——涵盖50年药物治疗的系统综述

Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment.
PubMed 文献 · Eur Heart J · 2019-01-01

综合来看,没有证据表明任何一种药物在治疗心绞痛或延长总运动持续时间方面优于另一种药物,仅三类药物显示等效性;指南结论并非来自证据而是来自临床信念。

要点

  • 没有证据表明任何抗心绞痛药物在改善运动耐量上优于另一种。
  • 仅β受体阻滞剂、钙拮抗剂和伊伐布雷定三类药物显示等效性证据。

核心结论

  • 现有证据未显示任何抗心绞痛药物在治疗心绞痛或延长总运动持续时间方面优于另一种药物。
  • 等效性证据仅见于β受体阻滞剂(阿替洛尔)、钙拮抗剂(氨氯地平、硝苯地平)和通道抑制剂(伊伐布雷定)三类药物。
  • 指南对抗心绞痛药物的推荐结论并非基于证据,而是基于临床信念。

研究设计与样本

  • 2018年1月至3月对Medline和Embase过去50年英文文献进行系统综述,遵循PRISMA和Cochrane协作方法。
  • 纳入标准为双盲随机平行组研究,比较稳定型冠心病患者的心绞痛治疗,样本量至少100例(每组50例),随访至少1周,结局采用运动试验测量,以运动持续时间为首选结局。

主要发现

  • 三项研究显示β受体阻滞剂(阿替洛尔)、钙拮抗剂(氨氯地平、硝苯地平)和通道抑制剂(伊伐布雷定)之间存在等效性证据。
  • 总体而言,没有一项研究提供证据表明一种药物在治疗心绞痛或延长总运动持续时间方面优于另一种药物。

临床怎么用

  • 当前指南推荐将β受体阻滞剂、钙通道阻滞剂和短效硝酸酯作为一线药物,长效硝酸酯、伊伐布雷定、尼可地尔、雷诺嗪和曲美他嗪作为二线药物。
  • 二线药物适用于对一线药物有禁忌、不耐受或仍有症状的患者。
  • 临床选择抗心绞痛药物时应认识到现有证据不足以支持一种药物优于另一种,需结合患者个体情况决策。

局限性

  • 系统综述仅纳入英文文献,可能存在语言偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic stable angina is the most prevalent symptom of ischaemic heart disease and its management is a priority. Current guidelines recommend pharmacological therapy with drugs classified as being first line (beta blockers, calcium channel blockers, short acting nitrates) or second line (long-acting nitrates, ivabradine, nicorandil, ranolazine, and trimetazidine). Second line drugs are indicated for patients who have contraindications to first line agents, do not tolerate them or remain symptomatic. Evidence that one drug is superior to another has been questioned. Between January and March 2018, we performed a systematic review of articles written in English over the past 50 years English-written articles in Medline and Embase following preferred reporting items and the Cochrane collaboration approach. We included double blind randomized studies comparing parallel groups on treatment of angina in patients with stable coronary artery disease, with a sample size of, at least, 100 patients (50 patients per group), with a minimum follow-up of 1 week and an outcome measured on exercise testing, duration of exercise being the preferred outcome. Thirteen studies fulfilled our criteria. Nine studies involved between 100 and 300 patients, (2818 in total) and a further four enrolled greater than 300 patients. Evidence of equivalence was demonstrated for the use of beta-blockers (atenolol), calcium antagonists (amlodipine, nifedipine), and channel inhibitor (ivabradine) in three of these studies. Taken all together, in none of the studies was there evidence that one drug was superior to another in the treatment of angina or to prolong total exercise duration. There is a paucity of data comparing the efficacy of anti-anginal agents. The little available evidence shows that no anti-anginal drug is superior to another and equivalence has been shown only for three classes of drugs. Guidelines draw conclusions not from evidence but from clinical beliefs.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019. PMID: 30165445. doi:10.1093/eurheartj/ehy504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。